Microbot Medical Inc. (Nasdaq: MBOT) filed a Current Report on Form 8-K on October 14, 2026, disclosing two primary updates regarding the company's governance and intellectual property portfolio.
Regarding corporate governance, the Board of Directors has scheduled the 2026 Annual Meeting of stockholders for December 14, 2026. The record date for determining shareholders entitled to vote at this meeting is October 15, 2026. Due to the change in meeting date exceeding 30 days from the anniversary of the previous year's meeting, the company established a new deadline for the receipt of qualified stockholder proposals. These proposals must be submitted to the company's principal executive offices in Hingham, Massachusetts, by the close of business on October 27, 2026. Additionally, any qualified stockholder seeking to nominate a director for the 2025 Annual Meeting must provide notice on a Schedule 14N and file it with the SEC by October 30, 2026.
In a separate disclosure under Regulation FD, the company announced on October 20, 2026, that it has received several new patent approvals across the United States, Japan, China, and Canada. As a result of these approvals, Microbot Medical now holds a total of 44 issued patents and 49 pending patent applications. These patents cover North America, Europe, Israel, and Asia. The company stated that these developments strengthen its global intellectual property portfolio as it continues to expand commercial adoption of the LIBERTY Endovascular Robotic System in the U.S. and positions the system for growth in international markets, including its pursuit of a CE Mark in the European Union.
